Background: GEP-NET are slow-growing tumors with heterogeneous presentation. Somatostatin analogs (SSAs) or watchful-waiting are recommended for management of unresectable, well-or moderatelydifferentiated non-functioning GEP-NET. This study aimed to develop a comprehensive shared-decision making MCDA-framework, and explore drivers of decision.
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Methods: A decision support tool was designed using a holistic MCDAframework (EVIDEM), literature review and insights from a Chatham-house panel of US physicians and patients with GEP-NET. A second extended panel (5 patients, 6 physicians) explored drivers of decision using two scenarios (SSA [reference case lanreotide] versus observation; lanreotide versus octreotide). Evidence was synthesized from a comprehensive literature review. Participants assigned weights through two techniques. For each criterion, participants were prompted to share experiential insights and knowledge, and assign a score (+5 [Much in favor of option 1] to -5 [Much in favor of option 2]). Value contributions (NormWeightXScore) were calculated for each criterion. Sensitivity analyses were performed.
Results: At group level, when exploring treatment over watchful-waiting, Type of therapeutic benefit, Disease severity, Effectiveness (mainly due to Progression-free survival and Disease symptom) and Quality of evidence favored treatment (mean value contribution: 0.08 ± SD 0.06, 0.07 ± 0.09, 0.07 ± 0.09 and 0.06 ± 0.06 respectively) whereas Costs aspects (interventions, medical and non-medical) favored watchful-waiting. When comparing two treatment options, the majority of criteria did not favor one option over another. System capacity (0.02 ± 0.02) and Non-medical costs and constraints (0.02 ± 0.03) tip the scale in favor of lanreotide and Cost of intervention in favor of octreotide (0.08 ± 0.12). Sub-criteria Impact on autonomy and Impact on dignity favored lanreotide. Wide SDs reflect variability of drivers of decision across participants.
Conclusion:
Exploration of scenarios identified drivers of decision for GEP-NET management and revealed the diversity of participants perspectives. Holistic MCDA embedded with evidence supports individual reflection and informed shared-decision making.
